Tdspharm Past Earnings Performance

Past criteria checks 2/6

Tdspharm has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 1.8% annually. Revenues have been declining at an average rate of 24.5% per year. Tdspharm's return on equity is 6.7%, and it has net margins of 11.6%.

Key information

13.87%

Earnings growth rate

-85.71%

EPS growth rate

Pharmaceuticals Industry Growth	11.32%
Revenue growth rate	-24.49%
Return on equity	6.72%
Net Margin	11.63%
Last Earnings Update	30 Jun 2025

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Tdspharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A464280 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 25	22,944	2,668	3,144	676
31 Mar 25	25,434	3,275	3,096	659
31 Dec 24	27,519	3,718	3,082	622
30 Sep 24	30,807	4,663	2,907	520
31 Mar 24	29,970	4,392	2,387	458
31 Dec 23	30,049	4,688	2,233	441
31 Dec 22	25,588	3,456	1,691	479
31 Dec 21	19,820	2,063	1,168	356
31 Dec 20	18,023	1,351	1,019	437
31 Dec 19	19,213	999	1,221	455
31 Dec 18	17,750	-848	1,573	339
31 Dec 17	15,520	1,655	1,490	357
31 Dec 16	13,853	1,172	1,217	687

Quality Earnings: A464280 has high quality earnings.

Growing Profit Margin: A464280's current net profit margins (11.6%) are lower than last year (14.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A464280's earnings have grown by 13.9% per year over the past 5 years.

Accelerating Growth: A464280's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A464280 had negative earnings growth (-41.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-18.1%).

Return on Equity

High ROE: A464280's Return on Equity (6.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/14 11:13
End of Day Share Price	2025/11/14 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tdspharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.